HAGE, the helicase antigen as a biomarker for breast cancer prognosis (WO2013144616).
Breast cancer (BC) is the most common cancer in women and it ranks second as a cause of cancer death in women (after lung cancer). The receptor-based diagnosis of BC tumors allows application of more individual therapies. Depending on the status of the receptors and other risk markers, like tumor size and lymph node status, patients are assigned to risk classes. Invention of new biomarkers that could improve diagnosis and prognosis of BC patients is thus of an increased need. The invention estimates the possibility of using the amount of expression of helicase antigen (HAGE) in samples of BC tissue as a biomarker for screening and prognosis. A total of 1650 BC patients were tested for HAGE expression and analyzed for well-characterized prognostic and predictive factors. HAGE expression was found to correlate significantly with aggressive clinicopathological features. A total of 443 triple negative patients were analyzed for therapeutic treatment received and survival. The HAGE expression was identified as a predictor of response to anthracycline treatment. The result was confirmed by comparison with an independent validation group. Тo identify patients who could be treated, a more detailed analysis taking into account, the full distribution spectrum of HAGE expression is desirable.